HC Wainwright Rates Unicycive Therapeutics (UNCY) buy
HC Wainwright maintains its buy rating on Unicycive Therapeutics with a $15 price target, a 211.29% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Unicycive Therapeutics, Inc. ($UNCY) "buy" with a $15 price target on June 30, 2026.
Since the rating, $UNCY is up 15.8% after 1 week, up 13.0% after 1 month and down 28.4% to date (from the $4.69 close on Jun 30, 2026).
UNCY
Unicycive Therapeutics, Inc.
Key Points
- HC Wainwright reiterated its buy rating for Unicycive Therapeutics, setting a price target of $15 on June 30, 2026.
- HC Wainwright's $15 price target implies 211.29% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- Shares of Unicycive Therapeutics traded near $4.59 on Wednesday, with a market cap of around $128.5 million.
- Insider buying includes CEO Shalabh Gupta acquiring 762,200 shares on May 14, 2026, with no price disclosed.
Get $UNCY trade alerts by text
We text you when insiders, Congress or big funds trade $UNCY. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Unicycive Therapeutics, Inc. alert may contain errors. Disclosures
HC Wainwright has reiterated its buy rating on Unicycive Therapeutics, Inc. (NASDAQ: UNC), maintaining a price target of $15. This update came on June 30, 2026, from analyst Swayampakula Ramakanth. Shares of Unicycive traded near $4.59 on Wednesday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Unicycive Therapeutics
Millennium Management LLC increased its holdings in Unicycive by 384,505 shares, bringing its total to 1,399,348 shares worth approximately $9.21 million, marking a 37.9% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 811,430 shares valued at about $5.34 million.
Unicycive Therapeutics, Inc. Stock Up 0.4%
On Wednesday, shares of Unicycive Therapeutics (NASDAQ: UNCY) traded near $4.59. The company has a market cap of approximately $128.5 million and a forward P/E ratio of 0.86. Its beta is 1.726, indicating higher volatility compared to the market. The stock's 52-week range is between $3.71 and $8.74, with a 50-day moving average of $7.56 and a 200-day moving average of $6.25. Unicycive has a current ratio of 2.4 and a quick ratio of 2.06, with a debt-to-equity ratio of 2.16.
$UNCY price target
Unicycive Therapeutics, Inc. daily closes and this analyst's $15 target. Not advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several insiders purchased shares of Unicycive Therapeutics. CEO Shalabh Gupta acquired 762,200 shares, while EVP of Pharmaceuticals and BD, Pramod Gupta, bought 169,500 shares. EVP of Corporate Strategy, Douglas Jermasek, also bought 169,500 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 30, 2026, HC Wainwright & Co. maintained its buy rating on Unicycive Therapeutics with a $15 price target. On the same day, B. Riley Securities also maintained a buy rating, setting a target of $22. Benchmark maintained its buy rating with an $18 target on June 2. The consensus among analysts is a strong buy, with a mean price target of $41.3 based on 10 analyst opinions.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing treatments for kidney diseases. Based in Mountain View, California, and led by CEO Dr. Pramod Gupta, the company is working on oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney injury. Founded in 2016, Unicycive is a clinical-stage firm with 21 employees.
Bottom Line
Unicycive Therapeutics remains on the radar of analysts like HC Wainwright, who reaffirmed their buy rating with a $15 target. The company's stock is showing volatility, typical of biotech firms, and is closely watched by investors for its innovative treatments in kidney disease. Keep in mind that analyst ratings and 13F filings provide a snapshot of past positions and sentiment, not necessarily current ones.
Related Filing Alerts
Source: HC Wainwright's rating change on $UNCY (Jun 30, 2026). Written by software, not financial advice. How we make alerts